Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
T-cell fitness is critical for myeloma survivors. And, according to the article linked below, continual myeloma treatments can exhaust t-cells. So what’s a MM survivor to do?
Considering that multiple myeloma is an incurable blood cancer, the FDA therapy plan for all newly diagnosed MM patients is to undergo toxic therapy after toxic therapy until the MM patient runs out of options-
confronting either-
Here are several approaches that can be considered to enhance T-cell fitness in myeloma patients:
Sadly, the therapies listed above cited to boost T-cell fitness are largely evidence-based non-conventional therapies. Meaning, none of these therapies is FDA approved and probable not be prescribed by the patient’s oncologist.
If you would like to learn more about non-conventional MM therapies email me a question or a comment at David.PeopleBeatingCancer@gmail.com
Thank you,
“Competent T-cells with sufficient levels of fitness combat cancer formation and progression. In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor burden, constant immune activation due to chronic disease, age, nutritional status, and certain MM treatments such as alkylating agents and proteasome inhibitors.
Many currently used therapies, including:
directly or indirectly depend on the anti-cancer activity of T-cells.
Reduced T-cell fitness not only diminishes immune defenses, increasing patient susceptibility to opportunistic infections, but can impact effectiveness MM therapy effectiveness, bringing into focus sequencing strategies that could modulate T-cell fitness and potentially optimize overall benefit and clinical outcomes…
Additional clinical studies are needed to understand how T-cell fitness is impacted by diseases and therapeutic factors in MM, to potentially facilitate the optimal use of available treatments that depend on, and impact, T-cell function. This review summarizes the importance of T-cell fitness and the potential to optimize treatment using T-cell engaging therapies with a focus on XPO1 inhibitors.,,
The importance of T-cell fitness
In the context of CAR-T therapy for hematological malignancies, T-cell fitness is the ability of a T-cell to generate an immune response that mediates the elimination of malignant cells and provides durable protection from relapse (5).
T-cell exhaustion is defined by poor effector function, and characterized by reduced T-cell proliferation, increased expression of inhibitory receptors such as checkpoint inhibitors, and a distinct transcriptional signature (4, 12).
In MM, disease progression is also associated with an altered T-cell repertoire including a reduction in bone marrow and peripheral blood effector T-cells, leading to an overall decrease in T-cell fitness (13)…
T-cell exhaustion has been a crucial limiting factor in hematologic malignancy studies utilizing autologous CAR-T therapy (5, 15, 16)…
T-cell fitness can be negatively affected by multiple factors, including prior treatments, increased age, malnutrition, and systemic inflammation (Figure 1)…
In bispecific antibody therapies, given that most of these agents have been developed with continuous therapy schedules, accumulating data also point to the relevance of treatment-free intervals in functional and transcriptional rejuvenation of T cells (27)…
CAR-T therapy and bispecific antibodies show promise in the treatment of hematologic malignancies, but efficacy is likely dependent on the status of a patient’s immune system, tumor microenvironment, and prior treatment history (4, 15, 67). T-cell exhaustion, driven by age, disease burden, and prior cancer treatment, is a critical limiting factor of these therapies (5)…